The rise of fentanyl and other synthetic opioids is unlike any drug crisis in U.S. history. Limiting policy responses to existing approaches will likely be insufficient and may condemn many people to early deaths.
In this RAND Remote presentation, Beau Kilmer discusses how RAND is identifying and evaluating innovative approaches to tackle some of our most pressing drug problems and help strengthen and safeguard communities.
In the context of the pandemic, buprenorphine prescribers quickly transitioned to providing telemedicine visits in high volume; nonetheless, there are still many unknowns, including the quality and safety of widespread use of telemedicine for OUD treatment.
The question for California isn't really if psychedelic policy will change, but more likely how—and how quickly. Now is the time for the California State Legislature to consider holding hearings on psychedelics and creating a commission to assess regulatory options.
This study aimed to To quantify the availability of telehealth services at substance use treatment facilities in the U.S. at the beginning of the COVID-19 pandemic, and determine whether telehealth is available at facilities in counties with the greatest amount of social distancing. Relatively few substance use treatment facilities offered telehealth services at the onset of the COVID-19 pandemic. Policymakers and public health officials should do more to support facilities in offering telehealth services.
We conducted a mixed-methods study that involved focus group interviews and an online survey disseminated to a random group of licensed U.S. physicians, which oversampled physicians with a preexisting waiver to prescribe buprenorphine.
We conducted an analysis on 342 young adults with past-year co-administration of tobacco/nicotine and marijuana to determine how emergent classes of 16 co-use motives were associated with use of tobacco/nicotine and marijuana one year later.
This study will evaluate whether the adapted intervention, also known as integrating support persons into recovery, is effective in increasing patient retention on buprenorphine when compared to usual care.
Although use of telemedicine for the treatment of opioid use disorders is growing, there is limited research on how it is actually being deployed in treatment. We explored how health centers across the U.S. are using it.
In this cross-sectional study with random assignment of clinicians and simulated-patient callers, many women, especially pregnant women, faced barriers to accessing treatment. Given the high out-of-pocket costs and lack of acceptance of insurance among many clinicians, access to affordable opioid use disorder treatment is a significant concern.
This cross-sectional study examines the number of patients prescribed buprenorphine by waivered-clinicians. Evidence shows waivered-clinicians who are able to prescribe buprenorphine treat fewer patients than their limit allows. With so much unmet demand for OUD treatment, this suggests the need for ongoing efforts to address treatment barriers.
This article proceeds in three parts: discussions of the general goals and role of public health tort litigation, the demonstrated and potential value of opioid litigation to achieve public health goals, and a conclusion.
Prescription opioid use and driving is a public health concern given the risks associated with drugged driving. We examined the prevalence and correlates of driving after taking prescription opioids among adults seeking emergency department treatment.